Toggle light / dark theme

Prevent Aging within 20 Years? — Altos Labs’ Cellular Reprogramming Excitement

A little confusing. Cure aging in 20 years but you’re not a longevity company?


Altos Labs recently exited stealth mode to announce $3 billion in funding, reportedly from investors including Jeff Bezos, and a team full of Nobel Prize winners and pioneering scientists. However, the secretive company’s representatives insist that “Altos is not an anti-aging or longevity company”. Despite this, a key member of their scientific leadership recently publicly stated that he is convinced that, using the same technologies they are working with at Altos, we will be able to prevent aging within twenty years.

The scientist making these bold statements is Juan Carlos Izpisua Belmonte, a Spanish biologist who has spent years pioneering innovations in developmental biology, regenerative medicine and aging research at the Salk Institute.

In 2006, a study showed that it was possible to reprogram cells using just four master genes. These four reprogramming factors are often called the Yamanaka factors after one of their discoverers, Shinya Yamanaka, who also happens to be part of the Altos Labs team.

In 2016, Belmonte and his team of researchers at the Salk Institute demonstrated that the cells and organs of a living animal could be rejuvenated using cellular reprogramming.

Altos Labs Explained: Jeff Bezos’ $3 Billion Gamble to Live Forever [Science Update March 2022]

How Jeff Bezos and Altos Labs are challenging death itself: The science of partial cellular reprogramming!


Hey it’s Han from WrySci-HX going over the science behind Altos Labs (the biotech company looking to extend healthspan and lifespan), news from the cultured meat industry, developments on a new device that can change your skin into nerve cells, and other science / technology happenings! More below ↓↓↓

Subscribe!

Please consider supporting 🙏

Patreon: https://www.patreon.com/wrysci_hx.

Get Ready For The Return-To-Office Showdown

After about three rounds of trying to get workers back to an office setting, this time it looks real. The uptick in Covid-19 cases caused the first foray into returning to headquarters to be pushed back. When things looked better, Delta and Omicron variant waves hit, forcing businesses to relent on their plans to get employees out of their homes and into cubicles.

Two years after the start of the pandemic, it looks like this time the executives will have their wish. Companies in all sectors—ranging from tech to Wall Street—are announcing their timelines for returning. The dominant style of work is the hybrid model, in which people will be asked to go to work for two or three days a week at their office and the rest of the time from home or wherever they so choose.

We will likely soon see a showdown. Many surveys over the last year or so showed that employees adamantly responded that they would rather quit than commute back to an office. It’s easier said than done. Saying something in a survey isn’t binding. You may have a preference of how you want to work, but it’s another thing to resign without another job lined up.

Senolytic drugs boost protein that protects against effects of aging

Senolytics are an emerging class of drugs designed to target zombie-like cells that have stopped dividing and build up in the body as we age, and the past few years have seen some exciting discoveries that demonstrate their potential. Adding another to the list are Mayo Clinic researchers, who have shown that these drugs can protect against aging and its related diseases, by acting on a protein long associated with longevity.

The zombie-like cells involved in this research are known as senescent cells, and their accumulation during aging is associated with a range of diseases. Recent studies have shown that using senolytics to clear them out could serve as new and effective treatments for dementia and diabetes, and also improve health and lifespan more broadly.

The Mayo Clinic team were exploring how senolytics can influence levels of a protein called a-klotho, known to help protect older people from the effects of aging. The role of this protein in the aging process is well established and has placed it at the center of much research in this space, with studies demonstrating how it could help reverse osteoarthritis and regenerate old muscles.

AI Maps Psychedelic ‘Trip’ Experiences to Regions of the Brain, Opening New Route to Psychiatric Treatments

Summary: AI technology helped map out diverse and subjective psychedelic experiences to different brain regions.

Source: The Conversation.

For the past several decades, psychedelics have been widely stigmatized as dangerous illegal drugs. But a recent surge of academic research into their use to treat psychiatric conditions is spurring a recent shift in public opinion.

You’re invited to join our subreddit community —

R/IntelligenceSupernova — dedicated to techno-optimists, singularitarians, transhumanist thinkers, cosmists, futurists, AI researchers, cyberneticists, crypto enthusiasts, VR creators, artists, philosophers of mind. Accelerating now towards the Cybernetic Singularity with unprecedented advances in AI & Cybernetics, VR, Biotechnology, Nanotechnology, Bionics, Genetic Engineering, Optogenetics, Neuroengineering, Robotics, and other IT fields.

Join now: https://www.reddit.com/r/IntelligenceSupernova.

#Subreddit #IntelligenceSupernova

AI drug algorithms can be flipped to generate bioweapons

What can heal can also be used to destroy?


MegaSyn is built to generate drug candidates with the lowest toxicity for patients. That got Urbina thinking. He retrained the model using data to drive the software toward generating lethal compounds, like nerve gas, and flipped the code so that it ranked its output from high-to-low toxicity. In effect, the software was told to come up with the most deadly stuff possible.

He ran the model and left it overnight to create new molecules.

It was quite impressive and scary at the same time, because in our list of the top 100, we were able to find some molecules that are VX analogues

/* */